Novartis Ag (NVS) Accounts Payables (2009 - 2025)
Novartis Ag recorded quarterly Accounts Payables of $4.5 billion in Q4 2025, down 1.11% quarter-over-quarter from $4.5 billion in Q2 2025, and down 2.54% year-over-year from $4.6 billion in Q4 2024.
Novartis Ag's Accounts Payables history runs 14 years deep, the most recent figure standing at $4.5 billion for Q4 2025.
- In Q4 2025, Accounts Payables fell 2.54% year-over-year to $4.5 billion; the TTM figure through Dec 2025 stood at $4.5 billion (down 2.54% YoY), while the FY2025 annual figure was $4.5 billion, down 2.54% from the prior year.
- Accounts Payables came in at $4.5 billion for Q4 2025 at Novartis Ag, down from $4.5 billion in the prior quarter.
- In the past five years, Accounts Payables ranged from a high of $5.6 billion in Q4 2021 to a low of $4.1 billion in Q2 2024.
- A 5-year average of $4.8 billion and a median of $4.9 billion in 2021 frame the typical range for Accounts Payables.
- Across the five-year window, Accounts Payables declined 22.5% in 2024 and climbed 8.68% in 2025, its largest moves.
- Novartis Ag's Accounts Payables stood at $5.6 billion in 2021, then declined by 7.33% to $5.1 billion in 2022, then fell by 4.28% to $4.9 billion in 2023, then retreated by 7.19% to $4.6 billion in 2024, then declined by 2.54% to $4.5 billion in 2025.
- According to Business Quant data, Accounts Payables over the past three periods registered $4.5 billion, $4.5 billion, and $4.6 billion for Q4 2025, Q2 2025, and Q4 2024 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Novartis Ag | 107,124,802.25 Bn | 107,124,802.25 Bn | - | - |
| 2 | Eli Lilly | 969.00 Bn | 963.72 Bn | 16.22 Bn | 5.03 Bn |
| 3 | Johnson & Johnson | 539.46 Bn | 517.41 Bn | 15.96 Bn | 10.46 Bn |
| 4 | AbbVie | 376.92 Bn | 367.57 Bn | 10.78 Bn | 33.77 Bn |
| 5 | Merck | 285.00 Bn | 279.35 Bn | 12.09 Bn | 3.86 Bn |
| 6 | Amgen | 177.58 Bn | 165.55 Bn | 5.87 Bn | 2.94 Bn |
| 7 | Gilead Sciences | 163.22 Bn | 155.50 Bn | 5.52 Bn | 645.00 Mn |
| 8 | Pfizer | 145.86 Bn | 133.09 Bn | -1.21 Bn | 4.51 Bn |
| 9 | Bristol Myers Squibb | 111.90 Bn | 101.44 Bn | 8.07 Bn | 4.23 Bn |
| 10 | Gsk | 88.34 Bn | 83.66 Bn | - | 20.46 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 4.46 Bn |
| Jun 30, 2025 | 4.51 Bn |
| Dec 31, 2024 | 4.57 Bn |
| Jun 30, 2024 | 4.15 Bn |
| Dec 31, 2023 | 4.93 Bn |
| Jun 30, 2023 | 5.35 Bn |
| Dec 31, 2022 | 5.15 Bn |
| Jun 30, 2022 | 4.97 Bn |
| Dec 31, 2021 | 5.55 Bn |
| Jun 30, 2021 | 4.81 Bn |
| Dec 31, 2020 | 5.40 Bn |
| Jun 30, 2020 | 4.82 Bn |
| Dec 31, 2019 | 5.42 Bn |
| Jun 30, 2019 | 4.75 Bn |
| Mar 31, 2019 | 735.00 Mn |
| Dec 31, 2018 | 5.56 Bn |
| Jun 30, 2018 | 5.49 Bn |
| Dec 31, 2017 | 5.17 Bn |
| Dec 31, 2016 | 4.87 Bn |
| Jun 30, 2015 | 215.00 |
| Mar 31, 2015 | 207.00 |
| Dec 31, 2013 | 50.00 |
| Mar 31, 2010 | 3,561.00 |
| Dec 31, 2009 | 4,012.00 |
| Sep 30, 2009 | 3,276.00 |
| Jun 30, 2009 | 3,320.00 |
| Mar 31, 2009 | 3,262.00 |